This review reinforces the role of parenteral hydralazine as a preferred, efficacious, and cost-effective agent for severe preeclampsia and accelerated hypertension.
Supports parenteral hydralazine preference in severe preeclampsia; leaves open need for updated comparative RCTs.
Historical aspects of the development and application of the vasodilator hydralazine are reviewed. The pharmacology, pharmacokinetics, metabolism, and mechanism of action are discussed, with emphasis on the parenteral use of this drug. It is reiterated that parenteral hydralazine is the preferred drug for the treatment of severe preeclampsia, but its usefulness in other forms of accelerated hypertension is also addressed. Through comparisons with other established antihypertensive agents, the efficacy and pharmacoeconomic potential of hydralazine are stressed.
No takes yet. Share an insight, caveat, or question.
Powers et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: